Marker Therapeutics (MRKR) Short term Debt (2010 - 2022)

Marker Therapeutics (MRKR) has 11 years of Short term Debt data on file, last reported at $2.5 million in Q4 2022.

• Short term Debt for Q4 2022 came in at $2.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $2.5 million (changed N/A YoY), and the FY2022 annual result was $2.5 million, changed N/A from the prior year.
• Short term Debt fell to $2.5 million in Q4 2022 per MRKR's latest filing, from $5.0 million in the prior quarter.
• Over five years, Short term Debt peaked at $8.0 million in Q2 2022 and troughed at $8000.0 in Q1 2018.
• A 3-year average of $1.5 million and a median of $107000.0 in 2018 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2018 and 2019: Short term Debt soared 1683.33% in 2018, then plunged 55.78% in 2019.
• A 3-year view of Short term Debt shows it stood at $49000.0 in 2018, then sank by 36.73% to $31000.0 in 2019, then surged by 7964.52% to $2.5 million in 2022.
• Business Quant data shows MRKR's Short term Debt at $2.5 million in Q4 2022, $5.0 million in Q3 2022, and $8.0 million in Q2 2022.